BRPI0909227B8 - uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl) - Google Patents

uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl)

Info

Publication number: BRPI0909227B8
Authority: BR; Brazil
Prior art keywords: antibody; vincristine; cyclophosphamide; doxorubicin; hodgkin
Prior art date: 2008-03-25

Application number

BRPI0909227A

Other languages

English (en)

Portuguese (pt)

Inventor

Dumontet Charles

Klein Christian

Herting Frank

Umana Pablo

Friess Thomas

Original Assignee

Roche Glycart Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-25

Filing date

2009-03-23

Publication date

2021-05-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40872445&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0909227(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-03-23 Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag

2015-12-01 Publication of BRPI0909227A2 publication Critical patent/BRPI0909227A2/pt

2020-11-24 Publication of BRPI0909227B1 publication Critical patent/BRPI0909227B1/pt

2021-05-25 Publication of BRPI0909227B8 publication Critical patent/BRPI0909227B8/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

BRPI0909227A 2008-03-25 2009-03-23 uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl) BRPI0909227B8 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP08005554.4		2008-03-25
EP08005554		2008-03-25
EP08007172		2008-04-11
EP08007172.3		2008-04-11
PCT/EP2009/002111 WO2009118142A1 (en)	2008-03-25	2009-03-23	Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas

Publications (3)

Publication Number	Publication Date
BRPI0909227A2 BRPI0909227A2 (pt)	2015-12-01
BRPI0909227B1 BRPI0909227B1 (pt)	2020-11-24
BRPI0909227B8 true BRPI0909227B8 (pt)	2021-05-25

Family

ID=40872445

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0909227A BRPI0909227B8 (pt)	2008-03-25	2009-03-23	uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl)

Country Status (31)

Country	Link
US (6)	US20090246197A1 (zh)
EP (1)	EP2268310B1 (zh)
JP (3)	JP5547709B2 (zh)
KR (1)	KR101280716B1 (zh)
CN (2)	CN107198772A (zh)
AR (1)	AR072947A1 (zh)
AU (1)	AU2009228616B2 (zh)
BR (1)	BRPI0909227B8 (zh)
CA (1)	CA2716884C (zh)
CL (1)	CL2009000713A1 (zh)
CR (1)	CR11687A (zh)
CY (1)	CY1117984T1 (zh)
DK (1)	DK2268310T3 (zh)
ES (1)	ES2592312T3 (zh)
HR (1)	HRP20161301T1 (zh)
HU (1)	HUE028828T2 (zh)
IL (1)	IL208018A (zh)
LT (1)	LT2268310T (zh)
MA (1)	MA32140B1 (zh)
MX (1)	MX2010009647A (zh)
MY (1)	MY163544A (zh)
NZ (1)	NZ587284A (zh)
PE (1)	PE20091821A1 (zh)
PL (1)	PL2268310T3 (zh)
PT (1)	PT2268310T (zh)
RS (1)	RS55258B1 (zh)
RU (1)	RU2589704C2 (zh)
SI (1)	SI2268310T1 (zh)
TW (1)	TWI500624B (zh)
WO (1)	WO2009118142A1 (zh)
ZA (1)	ZA201006190B (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA036531B1 (ru)	2003-11-05	2020-11-19	Роше Гликарт Аг	Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение
AR072947A1 (es) *	2008-03-25	2010-10-06	Glycart Biotechnology Ag	Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con citotoxicidad, celular dependiente de anticuerpos (ccda) aumentada, composicion farmaceutica, anticuerpo anti-cd20 de tipo ii
TW201014605A (en)	2008-09-16	2010-04-16	Genentech Inc	Methods for treating progressive multiple sclerosis
AR078161A1 (es)	2009-09-11	2011-10-19	Hoffmann La Roche	Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011153514A2 (en)	2010-06-03	2011-12-08	Pharmacyclics, Inc.	The use of inhibitors of bruton's tyrosine kinase (btk)
CA2819436A1 (en) *	2010-12-16	2012-06-21	Roche Glycart Ag	Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
US20130302274A1 (en) *	2011-11-25	2013-11-14	Roche Glycart Ag	Combination therapy
JP6575950B2 (ja)	2012-07-24	2019-09-18	ファーマサイクリックスエルエルシー	Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異
WO2015095410A1 (en) *	2013-12-17	2015-06-25	Genentech, Inc.	Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
US9732154B2 (en)	2014-02-28	2017-08-15	Janssen Biotech, Inc.	Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en)	2014-02-28	2017-03-28	Janssen Biotech, Inc.	Combination therapies with anti-CD38 antibodies
SG11201701867SA (en)	2014-09-09	2017-04-27	Janssen Biotech Inc	Combination therapies with anti-cd38 antibodies
WO2016089960A1 (en)	2014-12-04	2016-06-09	Janssen Biotech, Inc.	Anti-cd38 antibodies for treatment of acute myeloid leukemia
IL300548A (en)	2015-05-20	2023-04-01	Janssen Biotech Inc	Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
EA036789B1 (ru)	2015-06-22	2020-12-22	Янссен Байотек, Инк.	Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина
US20170044265A1 (en)	2015-06-24	2017-02-16	Janssen Biotech, Inc.	Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
TWI800341B (zh)	2015-11-03	2023-04-21	美商健生生物科技公司	抗cd38抗體之皮下調配物及其用途
US10781261B2 (en)	2015-11-03	2020-09-22	Janssen Biotech, Inc.	Subcutaneous formulations of anti-CD38 antibodies and their uses
CN108603037B (zh) *	2015-12-10	2020-11-17	希望之城	细胞穿透花青偶联抗体
AR110676A1 (es)	2016-10-07	2019-04-24	Novartis Ag	Tratamiento del cáncer utilizando receptores de antígenos quiméricos
US20180164221A1 (en)	2016-12-07	2018-06-14	Progenity Inc.	Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en)	2017-03-30	2021-05-13	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
KR20200079293A (ko)	2017-10-31	2020-07-02	얀센 바이오테크 인코포레이티드	고위험 다발성 골수종을 치료하는 방법
WO2019246312A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en)	2018-06-20	2023-01-12	Progenity, Inc.	Treatment of a disease or condition in a tissue orginating from the endoderm
CN116726361A (zh)	2018-11-19	2023-09-12	比奥拉治疗股份有限公司	用生物治疗剂治疗疾病的方法和装置
JPWO2021065568A1 (zh) *	2019-10-04	2021-04-08
WO2021119482A1 (en)	2019-12-13	2021-06-17	Progenity, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US5736137A (en) *	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU3657899A (en) *	1998-04-20	1999-11-08	James E. Bailey	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
RU2306952C2 (ru) *	2001-01-31	2007-09-27	Байоджен Айдек Инк.	Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
SI1558648T1 (sl) *	2002-10-17	2012-05-31	Genmab As	Človeška monoklonalna protitelesa proti CD
DE60332957D1 (de) *	2002-12-16	2010-07-22	Genentech Inc	Immunoglobulinvarianten und deren verwendungen
EA036531B1 (ru) *	2003-11-05	2020-11-19	Роше Гликарт Аг	Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение
DOP2006000029A (es) *	2005-02-07	2006-08-15	Genentech Inc	Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
CN101282993A (zh) *	2005-06-02	2008-10-08	阿斯利康公司	针对cd20的抗体和其用途
US20070071745A1 (en) *	2005-08-26	2007-03-29	Pablo Umana	Modified antigen binding molecules with altered cell signaling activity
KR101234436B1 (ko) *	2007-09-05	2013-02-18	로슈 글리카트 아게	유형 ⅰ 및 유형 ⅱ 항-ｃｄ２０ 항체를 사용하는 병용 치료요법
AR072947A1 (es) *	2008-03-25	2010-10-06	Glycart Biotechnology Ag	Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con citotoxicidad, celular dependiente de anticuerpos (ccda) aumentada, composicion farmaceutica, anticuerpo anti-cd20 de tipo ii

2009
- 2009-03-23 AR ARP090101035A patent/AR072947A1/es unknown
- 2009-03-23 CN CN201611215290.7A patent/CN107198772A/zh active Pending
- 2009-03-23 CA CA2716884A patent/CA2716884C/en active Active
- 2009-03-23 RS RS20160864A patent/RS55258B1/sr unknown
- 2009-03-23 TW TW098109412A patent/TWI500624B/zh active
- 2009-03-23 EP EP09723808.3A patent/EP2268310B1/en active Active
- 2009-03-23 JP JP2011501133A patent/JP5547709B2/ja active Active
- 2009-03-23 BR BRPI0909227A patent/BRPI0909227B8/pt active IP Right Grant
- 2009-03-23 RU RU2010143454/15A patent/RU2589704C2/ru active
- 2009-03-23 NZ NZ587284A patent/NZ587284A/en unknown
- 2009-03-23 PT PT97238083T patent/PT2268310T/pt unknown
- 2009-03-23 AU AU2009228616A patent/AU2009228616B2/en active Active
- 2009-03-23 WO PCT/EP2009/002111 patent/WO2009118142A1/en active Application Filing
- 2009-03-23 US US12/408,746 patent/US20090246197A1/en not_active Abandoned
- 2009-03-23 PL PL09723808T patent/PL2268310T3/pl unknown
- 2009-03-23 MY MYPI2010004461A patent/MY163544A/en unknown
- 2009-03-23 MX MX2010009647A patent/MX2010009647A/es active IP Right Grant
- 2009-03-23 CN CN2009801101810A patent/CN101983071A/zh active Pending
- 2009-03-23 KR KR1020107021332A patent/KR101280716B1/ko active IP Right Grant
- 2009-03-23 LT LTEP09723808.3T patent/LT2268310T/lt unknown
- 2009-03-23 HU HUE09723808A patent/HUE028828T2/en unknown
- 2009-03-23 SI SI200931530A patent/SI2268310T1/sl unknown
- 2009-03-23 DK DK09723808.3T patent/DK2268310T3/en active
- 2009-03-23 CL CL2009000713A patent/CL2009000713A1/es unknown
- 2009-03-23 ES ES09723808.3T patent/ES2592312T3/es active Active
- 2009-03-24 PE PE2009000437A patent/PE20091821A1/es not_active Application Discontinuation
2010
- 2010-05-10 US US12/777,141 patent/US20100310581A1/en not_active Abandoned
- 2010-08-30 ZA ZA2010/06190A patent/ZA201006190B/en unknown
- 2010-09-03 MA MA33145A patent/MA32140B1/fr unknown
- 2010-09-06 IL IL208018A patent/IL208018A/en active IP Right Grant
- 2010-09-23 CR CR11687A patent/CR11687A/es unknown
2011
- 2011-03-07 US US13/042,305 patent/US20110177067A1/en not_active Abandoned
- 2011-10-28 US US13/284,415 patent/US20120301459A1/en not_active Abandoned
2013
- 2013-03-14 US US13/829,409 patent/US20140065134A1/en not_active Abandoned
2014
- 2014-01-24 JP JP2014011332A patent/JP5912142B2/ja active Active
- 2014-06-05 US US14/297,478 patent/US20160000911A1/en not_active Abandoned
2016
- 2016-03-18 JP JP2016055096A patent/JP6154039B2/ja active Active
- 2016-09-07 CY CY20161100889T patent/CY1117984T1/el unknown
- 2016-10-10 HR HRP20161301TT patent/HRP20161301T1/hr unknown

Also Published As

Publication number	Publication date
JP2011515428A (ja)	2011-05-19
EP2268310A1 (en)	2011-01-05
JP2014101370A (ja)	2014-06-05
PL2268310T3 (pl)	2017-08-31
SI2268310T1 (sl)	2016-11-30
CN101983071A (zh)	2011-03-02
JP5547709B2 (ja)	2014-07-16
HRP20161301T1 (hr)	2016-11-18
JP2016121183A (ja)	2016-07-07
CN107198772A (zh)	2017-09-26
TWI500624B (zh)	2015-09-21
CA2716884A1 (en)	2009-10-01
MA32140B1 (fr)	2011-03-01
US20160000911A1 (en)	2016-01-07
JP5912142B2 (ja)	2016-04-27
US20090246197A1 (en)	2009-10-01
CR11687A (es)	2011-01-10
CA2716884C (en)	2017-10-03
MX2010009647A (es)	2010-09-28
DK2268310T3 (en)	2016-08-15
EP2268310B1 (en)	2016-07-20
RU2010143454A (ru)	2012-05-10
US20100310581A1 (en)	2010-12-09
PT2268310T (pt)	2016-08-23
WO2009118142A1 (en)	2009-10-01
US20120301459A1 (en)	2012-11-29
JP6154039B2 (ja)	2017-06-28
LT2268310T (lt)	2016-09-26
BRPI0909227B1 (pt)	2020-11-24
KR20100121525A (ko)	2010-11-17
US20110177067A1 (en)	2011-07-21
RS55258B1 (sr)	2017-02-28
US20140065134A1 (en)	2014-03-06
AR072947A1 (es)	2010-10-06
BRPI0909227A2 (pt)	2015-12-01
PE20091821A1 (es)	2009-11-25
AU2009228616A1 (en)	2009-10-01
NZ587284A (en)	2012-05-25
IL208018A (en)	2017-12-31
ZA201006190B (en)	2018-11-28
KR101280716B1 (ko)	2013-07-01
TW200951141A (en)	2009-12-16
AU2009228616B2 (en)	2014-07-24
HUE028828T2 (en)	2017-01-30
RU2589704C2 (ru)	2016-07-10
CL2009000713A1 (es)	2010-04-09
MY163544A (en)	2017-09-29
CY1117984T1 (el)	2017-05-17
IL208018A0 (en)	2010-12-30
ES2592312T3 (es)	2016-11-29

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-06-18	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2020-04-07	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-09-29	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-11-24	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

Publication	Publication Date	Title
BRPI0909227B8 (pt)	2021-05-25	uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl)
HRP20192058T1 (hr)	2020-02-21	Kombinirane terapije s anti-cd38 antitijelima
ATE526987T1 (de)	2011-10-15	Dr5-antikörper und deren verwendung
WO2007053573A3 (en)	2007-12-21	Treatment of cancer with sorafenib
CL2012002012A1 (es)	2012-11-05	Anticuerpo anti-cd38 o fragmento de este, capaz de destruir una célula cd38+ por apoptosis, citotoxicidad celular adcc y citotoxicidad cdc; anticuerpo humanizado; polinucleótido, vector y célula huésped que lo codifican; conjugado del anticuerpo con un compuesto citotóxico; composición farmacéutica con dichos anticuerpos; uso de los anticuerpos para tratar cáncer o enfermedad autoinmune; método para diagnosticar cáncer.
MX2010003815A (es)	2010-08-04	Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2.
NZ718826A (en)	2019-10-25	Pyrrolobenzodiazepines and conjugates thereof
AR071733A1 (es)	2010-07-14	Terapia combinada de un anticuerpo anti-cd20 tipo ii con un inhibidor de proteasoma
EA032934B1 (ru)	2019-08-30	Применение комбинации, содержащей специфически распознающее cd38 антитело и циклофосфамид
MX2015005555A (es)	2015-11-30	Combinacion de anticuerpo anti-cd20 e inhibidor selectivo de pi3 cinasa.
JO3291B1 (ar)	2018-09-16	الأجسام المضادة لـ csf-1r
ATE459653T1 (de)	2010-03-15	Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen
SG160412A1 (en)	2010-04-29	Anti-igfr1 antibody therapeutic combinations
MX2009003774A (es)	2009-04-22	Anticuerpos para linfotoxina-alfa.
AR073425A1 (es)	2010-11-03	Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina
RU2014123781A (ru)	2015-12-27	Комбинированная терапия с применением антитела к cd20 и человеческого il-15
BR112015027474A2 (pt)	2017-12-05	obinutuzumab, composição, obinutuzumab em combinação com o conjugado de anticorpo-fármaco cd22 anti-cd22-mc-vc-pab-mmae e uso de obinutuzumab em combinação com o conjugado de anticorpo-fármaco cd22 anti-cd22-mc-vc-pab-mmae
MX2009010271A (es)	2009-10-12	Tratamiento combinado del cancer con anticuerpo anti cd20 e interleucina 18 humana.
BR112022008756A2 (pt)	2022-07-26	Conjugados anticorpo-fármaco anti-mesotelina eribulina e métodos de uso
MX2021010313A (es)	2021-09-23	Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
MX2017011882A (es)	2018-04-20	Composiciones y metodos para focalizar cd99 en malignidades hematopoyeticas y linfoides.
WO2007007152A3 (en)	2007-04-19	Anti-madcam antibodies to treat metastatic cancers and chloroma
TH125072B (th)	2013-06-28	การรักษาโดยการใช้ร่วมกันของสารภูมิต้านทาน cd20 ชนิดที่ 2 ที่มีความเป็นพิษ ต่อเซลล์ โดยอาศัยสารภูมิต้านทาน (adcc)ที่เพิ่มขึ้น
Carlson	2010	Immunoconjugates: Rapidly Changing & Promising Field
TW200640948A (en)	2006-12-01	DR5 antibodies and uses thereof